Full Text View
Tabular View
No Study Results Posted
Related Studies
Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)
This study is ongoing, but not recruiting participants.
Study NCT01502982   Information provided by Nordic Lymphoma Group

First Received on December 21, 2011.   Last Updated on January 3, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diffuse Large B-Cell Lymphoma
Additional conditions recognized in this trial
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
R-CHOEP14x6+HD-AraC+HD-Mtx
Additional drug interventions recognized in this trial
Rituximab
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Nordic Lymphoma Group
Amgen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services